Effect of <i>CTLA4</i> gene polymorphism on relapse probability among patients with acute leukemias after allogenic hematopoietic stem cells transplantation
Background. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is being widely applied as a therapy for hematological malignancies. The long-term outcome of allo-HSCT depends directly on the ability of cytotoxic T-lymphocytes to recognize and eliminate the residual tumor. CTLA-4 is one o...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-04-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/337 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839574448596844544 |
|---|---|
| author | D. S. Romaniuk A. A. Khmelevskaya M. Yu. Drokov N. N. Popova V. A. Vasilieva L. A. Kuzmina G. A. Efimov E. N. Parovichnikova V. G. Savchenko |
| author_facet | D. S. Romaniuk A. A. Khmelevskaya M. Yu. Drokov N. N. Popova V. A. Vasilieva L. A. Kuzmina G. A. Efimov E. N. Parovichnikova V. G. Savchenko |
| author_sort | D. S. Romaniuk |
| collection | DOAJ |
| description | Background. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is being widely applied as a therapy for hematological malignancies. The long-term outcome of allo-HSCT depends directly on the ability of cytotoxic T-lymphocytes to recognize and eliminate the residual tumor. CTLA-4 is one of the regulatory proteins that provide control over the development of the immune response. Polymorphisms in the CTLA4 gene can affect its function and the efficiency of the antitumor response. The objective: to study the effect of non-synonymous single nucleotide polymorphism (nsSNP) c.49A>G in the donor CTLA4 gene on tumor control in the recipient of allogeneic hematopoietic stem cells (HSC). Materials and methods. Donors of HSC were genotyped for nsSNP c.49A>G in the CTLA4 gene by the real-time polymerase chain reaction using the allele-specific primers. Genotyping data was validated by Sanger’s sequencing of 22 randomly selected samples. The overall survival, the event-free survival and relapse probability were calculated using the Kaplan–Mayer method. A log-rank test was used to assess the statistical significance of group disparities. A p-value of 0.05 was considered as significant. Results. The frequencies of the CTLA4 gene c.49A>G polymorphism alleles in the observed population (102 healthy donors of HSC) correspond to the frequencies obtained by the “1000 genomes” project for the European population. The effect of the donor CTLA4 polymorphism on the tumor control was evaluated on the cohort of patients with acute leukemia after human leukocyte antigen (HLA) matched HSCT from an unrelated donor. It was shown, the three-year relapse-free survival was significantly lower for those patients who received grafts from a donor with the homozygous A/A state of nsSNP c.49A>G (p = 0.01), it was 12.7 % versus 62,8 % in group with c.49A>G G/G and A/G donor genotypes. The incidence of relapse was also significantly different for the group with A/A genotype and for the group with G/G or A/G genotypes of the nsSNP and equaled to 83.7 and 29.3 % respectively (p = 0.03). Conclusion. Patients with acute leukemia, who underwent allo-HSCT from unrelated completely HLA-matched donors with c.49A>G G/G or A/G genotypes have the significantly lower risk of relapse than patients whose donors had the A/A genotype. These results suggest practicability of the nsSNP genotyping for the optimal donor selection. |
| format | Article |
| id | doaj-art-1c51bc7aaee94e558d4ac9e6c9b7ebdb |
| institution | Matheson Library |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2019-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-1c51bc7aaee94e558d4ac9e6c9b7ebdb2025-08-04T13:57:50ZrusABV-pressОнкогематология1818-83462413-40232019-04-01141768210.17650/1818-8346-2019-14-1-76-82306Effect of <i>CTLA4</i> gene polymorphism on relapse probability among patients with acute leukemias after allogenic hematopoietic stem cells transplantationD. S. Romaniuk0A. A. Khmelevskaya1M. Yu. Drokov2N. N. Popova3V. A. Vasilieva4L. A. Kuzmina5G. A. Efimov6E. N. Parovichnikova7V. G. Savchenko8National Research Center for Hematology, Ministry of Health of Russia; 4 Novyy Zykovskiy Proezd, Moscow 125167National Research Center for Hematology, Ministry of Health of Russia; 4 Novyy Zykovskiy Proezd, Moscow 125167National Research Center for Hematology, Ministry of Health of Russia; 4 Novyy Zykovskiy Proezd, Moscow 125167National Research Center for Hematology, Ministry of Health of Russia; 4 Novyy Zykovskiy Proezd, Moscow 125167National Research Center for Hematology, Ministry of Health of Russia; 4 Novyy Zykovskiy Proezd, Moscow 125167National Research Center for Hematology, Ministry of Health of Russia; 4 Novyy Zykovskiy Proezd, Moscow 125167National Research Center for Hematology, Ministry of Health of Russia; 4 Novyy Zykovskiy Proezd, Moscow 125167National Research Center for Hematology, Ministry of Health of Russia; 4 Novyy Zykovskiy Proezd, Moscow 125167National Research Center for Hematology, Ministry of Health of Russia; 4 Novyy Zykovskiy Proezd, Moscow 125167Background. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is being widely applied as a therapy for hematological malignancies. The long-term outcome of allo-HSCT depends directly on the ability of cytotoxic T-lymphocytes to recognize and eliminate the residual tumor. CTLA-4 is one of the regulatory proteins that provide control over the development of the immune response. Polymorphisms in the CTLA4 gene can affect its function and the efficiency of the antitumor response. The objective: to study the effect of non-synonymous single nucleotide polymorphism (nsSNP) c.49A>G in the donor CTLA4 gene on tumor control in the recipient of allogeneic hematopoietic stem cells (HSC). Materials and methods. Donors of HSC were genotyped for nsSNP c.49A>G in the CTLA4 gene by the real-time polymerase chain reaction using the allele-specific primers. Genotyping data was validated by Sanger’s sequencing of 22 randomly selected samples. The overall survival, the event-free survival and relapse probability were calculated using the Kaplan–Mayer method. A log-rank test was used to assess the statistical significance of group disparities. A p-value of 0.05 was considered as significant. Results. The frequencies of the CTLA4 gene c.49A>G polymorphism alleles in the observed population (102 healthy donors of HSC) correspond to the frequencies obtained by the “1000 genomes” project for the European population. The effect of the donor CTLA4 polymorphism on the tumor control was evaluated on the cohort of patients with acute leukemia after human leukocyte antigen (HLA) matched HSCT from an unrelated donor. It was shown, the three-year relapse-free survival was significantly lower for those patients who received grafts from a donor with the homozygous A/A state of nsSNP c.49A>G (p = 0.01), it was 12.7 % versus 62,8 % in group with c.49A>G G/G and A/G donor genotypes. The incidence of relapse was also significantly different for the group with A/A genotype and for the group with G/G or A/G genotypes of the nsSNP and equaled to 83.7 and 29.3 % respectively (p = 0.03). Conclusion. Patients with acute leukemia, who underwent allo-HSCT from unrelated completely HLA-matched donors with c.49A>G G/G or A/G genotypes have the significantly lower risk of relapse than patients whose donors had the A/A genotype. These results suggest practicability of the nsSNP genotyping for the optimal donor selection.https://oncohematology.abvpress.ru/ongm/article/view/337allogeneic hematopoietic stem cell transplantationgraft versus host diseaseallele-specific polymerase chain reactionnonsynonymous single nucleotide polymorphismctla4 |
| spellingShingle | D. S. Romaniuk A. A. Khmelevskaya M. Yu. Drokov N. N. Popova V. A. Vasilieva L. A. Kuzmina G. A. Efimov E. N. Parovichnikova V. G. Savchenko Effect of <i>CTLA4</i> gene polymorphism on relapse probability among patients with acute leukemias after allogenic hematopoietic stem cells transplantation Онкогематология allogeneic hematopoietic stem cell transplantation graft versus host disease allele-specific polymerase chain reaction nonsynonymous single nucleotide polymorphism ctla4 |
| title | Effect of <i>CTLA4</i> gene polymorphism on relapse probability among patients with acute leukemias after allogenic hematopoietic stem cells transplantation |
| title_full | Effect of <i>CTLA4</i> gene polymorphism on relapse probability among patients with acute leukemias after allogenic hematopoietic stem cells transplantation |
| title_fullStr | Effect of <i>CTLA4</i> gene polymorphism on relapse probability among patients with acute leukemias after allogenic hematopoietic stem cells transplantation |
| title_full_unstemmed | Effect of <i>CTLA4</i> gene polymorphism on relapse probability among patients with acute leukemias after allogenic hematopoietic stem cells transplantation |
| title_short | Effect of <i>CTLA4</i> gene polymorphism on relapse probability among patients with acute leukemias after allogenic hematopoietic stem cells transplantation |
| title_sort | effect of i ctla4 i gene polymorphism on relapse probability among patients with acute leukemias after allogenic hematopoietic stem cells transplantation |
| topic | allogeneic hematopoietic stem cell transplantation graft versus host disease allele-specific polymerase chain reaction nonsynonymous single nucleotide polymorphism ctla4 |
| url | https://oncohematology.abvpress.ru/ongm/article/view/337 |
| work_keys_str_mv | AT dsromaniuk effectofictla4igenepolymorphismonrelapseprobabilityamongpatientswithacuteleukemiasafterallogenichematopoieticstemcellstransplantation AT aakhmelevskaya effectofictla4igenepolymorphismonrelapseprobabilityamongpatientswithacuteleukemiasafterallogenichematopoieticstemcellstransplantation AT myudrokov effectofictla4igenepolymorphismonrelapseprobabilityamongpatientswithacuteleukemiasafterallogenichematopoieticstemcellstransplantation AT nnpopova effectofictla4igenepolymorphismonrelapseprobabilityamongpatientswithacuteleukemiasafterallogenichematopoieticstemcellstransplantation AT vavasilieva effectofictla4igenepolymorphismonrelapseprobabilityamongpatientswithacuteleukemiasafterallogenichematopoieticstemcellstransplantation AT lakuzmina effectofictla4igenepolymorphismonrelapseprobabilityamongpatientswithacuteleukemiasafterallogenichematopoieticstemcellstransplantation AT gaefimov effectofictla4igenepolymorphismonrelapseprobabilityamongpatientswithacuteleukemiasafterallogenichematopoieticstemcellstransplantation AT enparovichnikova effectofictla4igenepolymorphismonrelapseprobabilityamongpatientswithacuteleukemiasafterallogenichematopoieticstemcellstransplantation AT vgsavchenko effectofictla4igenepolymorphismonrelapseprobabilityamongpatientswithacuteleukemiasafterallogenichematopoieticstemcellstransplantation |